Goldman Sachs analyst Olivier Nicolai upgraded Haleon (HLN) to Buy from Neutral with a 440 GBp price target The firm sees the company’s fundamentals inflecting in fiscal 2026 due to stronger volume, a U.S. recovery and ongoing high-single-digit Oral Health growth. With Haleon’s organic sales growth positioned to accelerate into 2026, the shares are trading at an attractive entry point, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLN: